slv-313
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00581243)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
HTR1A agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-((5-(4-fluorophenyl)-3-pyridinyl)methyl)piperazine
- slv313
- slv 313
- slv-313
- slv-313
- slv-313
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00620568 | Phase 1 | Feb 1, 2008 | Pfizer, Solvay, Wyeth |
| NCT00581243 | Phase 1 | Jan 1, 2008 | Pfizer, Solvay, Wyeth |
Showing 2 of 2 trials
Page 1 / 1